FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants

Journal of Neurology

Volumn 261, Issue 4, 2014, Pages 710-716

  Zalewski, Nicholas ^a   Botha, Hugo ^a   Whitwell, Jennifer L ^a   Lowe, Val ^a   Dickson, Dennis W ^b   Josephs, Keith A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

4R Tauopathy; CBD; FDG PET; GGT; PSP; Tau

Indexed keywords

FLUORODEOXYGLUCOSE; TAU PROTEIN; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN METABOLISM; CAUDATE NUCLEUS; CLINICAL ARTICLE; CORTICOBASAL DEGENERATION; DISEASE DURATION; FEMALE; GLOBULAR GLIAL TAUOPATHY; HUMAN; HUMAN TISSUE; IMAGING SOFTWARE; MALE; MESENCEPHALON; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; PARIETAL CORTEX; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PREMOTOR CORTEX; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; TAUOPATHY; THALAMUS; VERY ELDERLY; BRAIN LEVEL; DIAGNOSTIC USE; GLIA; METABOLISM; ONSET AGE; SCINTISCANNING;

AGE OF ONSET; AGED; AGED, 80 AND OVER; AUTOPSY; BRAIN CHEMISTRY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEUROGLIA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAUOPATHIES;

EID: 84898840436     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7256-4     Document Type: Article

References (25)

1. Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS (1997) Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 48(4):959-969
2. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I (1994) Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 44(11):2015-2019 (Pubitemid 24349498)
3. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ (2005) Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain J Neurol 128(Pt 6):1247-1258. doi: 10.1093/brain/awh488 (Pubitemid 40826179)
4. Ahmed Z, Bigio EH, Budka H, Dickson DW, Ferrer I, Ghetti B, Giaccone G, Hatanpaa KJ, Holton JL, Josephs KA, Powers J, Spina S, Takahashi H, White CL 3rd, Revesz T, Kovacs GG (2013) Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol. doi: 10.1007/s00401-013-1171-0
5. Coulier IM, de Vries JJ, Leenders KL (2003) Is FDG-PET a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration? Mov Disord Off J Mov Disord Soc 18(10):1175-1178. doi: 10.1002/mds.10498 (Pubitemid 37336943)
6. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, Eidelberg D (2005) FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage 26(3):912-921. doi: 10.1016/j.neuroimage.2005.03.012 (Pubitemid 40825033)
7. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA (1988) Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 24(3):399-406. doi: 10.1002/ana.410240308
8. Foster NL, Minoshima S, Johanns J, Little R, Heumann ML, Kuhl DE, Gilman S (2000) PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology 54(9):1768-1773 (Pubitemid 30428403)
9. Garraux G, Salmon E, Peigneux P, Kreisler A, Degueldre C, Lemaire C, Destee A, Franck G (2000) Voxel-based distribution of metabolic impairment in corticobasal degeneration. Mov Disord Off J Mov Disord Soc 15(5):894-904
10. Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W, Spehl TS, Rijntjes M, Hellwig B, Weiller C, Winkler C, Weber WA, Tuscher O, Meyer PT (2012) [(1)(8)F]FDG-PET is superior to [(1)(2)(3)I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 79(13):1314-1322. doi: 10.1212/WNL.0b013e31826c1b0a
11. Hosaka K, Ishii K, Sakamoto S, Mori T, Sasaki M, Hirono N, Mori E (2002) Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration. J Neurol Sci 199(1-2):67-71 (Pubitemid 34663837)
12. Juh R, Kim J, Moon D, Choe B, Suh T (2004) Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 51(3):223-233. doi: 10.1016/s0720-048x(03)00214-6 (Pubitemid 39037273)
13. Juh R, Pae CU, Kim TS, Lee CU, Choe B, Suh T (2005) Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosci Lett 383(1-2):22-27. doi: 10.1016/j.neulet.2005.03.057 (Pubitemid 40779949)
14. Klein RC, de Jong BM, de Vries JJ, Leenders KL (2005) Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson's disease. Mov Disord Off J Mov Disord Soc 20(8):1021-1030. doi: 10.1002/mds.20493 (Pubitemid 41419520)
15. Mishina M, Ishii K, Mitani K, Ohyama M, Yamazaki M, Ishiwata K, Senda M, Kobayashi S, Kitamura S, Katayama Y (2004) Midbrain hypometabolism as early diagnostic sign for progressive supranuclear palsy. Acta Neurol Scand 110(2):128-135. doi: 10.1111/j.1600-0404.2004.00293.x (Pubitemid 39044051)
16. Srulijes K, Reimold M, Liscic RM, Bauer S, Dietzel E, Liepelt-Scarfone I, Berg D, Maetzler W (2012) Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism. Mov Disord Off J Mov Disord Soc 27(1):151-155
17. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, Dhawan V, Lesser M, Vonsattel JP, Fahn S, Eidelberg D (2010) Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 9(2):149-158. doi: 10.1016/s1474-4422(10)70002-8
18. Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, van Oostrom JC, Leenders KL (2010) Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord Off J Mov Disord Soc 25(14):2395-2404. doi: 10.1002/mds.23291
19. Tripathi M, Dhawan V, Peng S, Kushwaha S, Batla A, Jaimini A, D'Souza MM, Sharma R, Saw S, Mondal A (2013) Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology 55(4):483-492. doi: 10.1007/s00234-012-1132-7
20. Turaga SP, Mridula R, Borgohain R (2013) Cerebral glucose metabolism, clinical, neuropsychological, and radiological profile in patients with corticobasal syndrome. Neurol India 61(1):7-11. doi: 10.4103/0028-3886.107916
21. Zhao P, Zhang B, Gao S (2012) 18F-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes. Parkinsonism Relat Disord 18(Suppl 1):S60-S62. doi: 10.1016/s1353-8020(11)70020-7
22. Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA (2010) Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 23(4):394-400. doi: 10.1097/WCO.0b013e32833be924
23. Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE, Hauser MF, Witte RJ, Boeve BF, Knopman DS, Dickson DW, Jack CR Jr, Petersen RC (2006) Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain J Neurol 129(Pt 6):1385-1398. doi: 10.1093/brain/awl078 (Pubitemid 43999372)
24. Josephs KA, Katsuse O, Beccano-Kelly DA, Lin WL, Uitti RJ, Fujino Y, Boeve BF, Hutton ML, Baker MC, Dickson DW (2006) A typical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol 65(4):396-405 (Pubitemid 44264836)
25. Botha H, Whitwell JL, Madhaven A, Senjem ML, Lowe V, Josephs KA (2013) The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism Relat Disord. doi: 10.1016/j.parkreldis.2013.10.023 [Epub ahead of print]